NTRK1 and neoplasm: The limited number of studies on TKI-based sequence treatment suggests that the overexpression of receptor tyrosine kinases (RTKs) following first-line treatment may increase the sensitivity of tumor cells to cabozantinib in second-line treatment [12,30,38].